Skip to main content
SpringerLink
Log in

Low-level vancomycin resistance in Staphylococcus aureus—an Australian perspective

  • Review
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Low-level vancomycin resistance in Staphylococcus aureus has emerged as a clinical problem over the past 8 years. The clinical relevance of this resistance has been questioned, and laboratory detection remains difficult and time consuming. There is, however, increasing evidence linking low-level vancomycin resistance with glycopeptide treatment failure in serious Staphylococcus aureus infections. Diagnostic laboratories and clinicians need to be aware of this resistance phenotype, to have procedures in place to detect the resistance, and to have strategies for managing patients with infections caused by resistant strains.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Anonymous (2002) Staphylococcus aureus resistant to vancomycin—United States, 2002. Morb Mortal Wkly Rep 51:565–567

    Google Scholar 

  2. Anonymous (2002) Vancomycin-resistant Staphylococcus aureus—Pennsylvania, 2002. Morb Mortal Wkly Rep 51:902

    Google Scholar 

  3. Anonymous (2004) Vancomycin-resistant Staphylococcus aureus—New York, 2004. Morb Mortal Wkly Rep 53:322–323

    Google Scholar 

  4. Ward PB, Johnson PD, Grabsch EA, Mayall BC, Grayson ML (2001) Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med J Aust 175:480–483

    Google Scholar 

  5. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP (2001) A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 47:399–403

    Article  Google Scholar 

  6. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P et al (2004) Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38:521–8

    Google Scholar 

  7. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML (2004) Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38:448–451

    Google Scholar 

  8. Kaatz GW, Seo SM, Dorman NJ, Lerner SA (1990) Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 162:103–108

    Google Scholar 

  9. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135–136

    Article  CAS  PubMed  Google Scholar 

  10. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S et al (1997) Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670–1673

    Article  Google Scholar 

  11. Hiramatsu K (2001) Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 1:147–155

    Google Scholar 

  12. Walsh TR, Howe RA (2002) The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Ann Rev Microbiol 56:657–675

    Article  Google Scholar 

  13. National Committee for Clinical Laboratory Standards (2004) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. NCCLS, Wayne, PA

    Google Scholar 

  14. Tenover FC, Biddle JW, Lancaster MV (2001) Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 7:327–332

    Google Scholar 

  15. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP (2001) A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 47:399–403

    Article  Google Scholar 

  16. Sieradzki K, Roberts RB, Haber SW, Tomasz A (1999) The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 340:517–523

    Article  Google Scholar 

  17. Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM et al (2003) Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41:5–14

    Article  Google Scholar 

  18. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K (1998) Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 42:199–209

    Article  Google Scholar 

  19. Sieradzki K, Tomasz A (2003) Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol 185:7103–7110

    Article  Google Scholar 

  20. Boyle-Vavra S, Challapalli M, Daum RS (2003) Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance. Antimicrob Agents Chemother 47:2036–2039

    Article  Google Scholar 

  21. Howe RA, Monk A, Wootton M, Walsh TR, Enright MC (2004) Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis 10:855–857

    Google Scholar 

  22. Kuroda M, Kuwahara-Arai K, Hiramatsu K (2000) Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method. Biochem Biophys Res Commun 269:485–490

    Article  Google Scholar 

  23. Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K (2003) Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol 49:807–821

    Article  Google Scholar 

  24. Bischoff M, Roos M, Putnik J, Wada A, Glanzmann P, Giachino P et al (2001) Involvement of multiple genetic loci in Staphylococcus aureus teicoplanin resistance. FEMS Microbiol Lett 194:77–82

    Article  Google Scholar 

  25. Mongodin E, Finan J, Climo MW, Rosato A, Gill S, Archer GL (2003) Microarray transcription analysis of clinical Staphylococcus aureus isolates resistant to vancomycin. J Bacteriol 185:4638–4643

    Article  Google Scholar 

  26. Ike Y, Arakawa Y, Ma X, Tatewaki K, Nagasawa M, Tomita H et al (2001) Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J Clin Microbiol 39:4445–4451

    Article  Google Scholar 

  27. Arakawa Y, Ike Y, Nagasawa M (2004) Where has vancomycin-heterogeneously resistant Staphylococcus aureus gone? Lancet 363:1401

    Article  Google Scholar 

  28. Hubert SK, Mohammed JM, Fridkin SK, Gaynes RP, McGowan JE Jr, Tenover FC (1999) Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals. J Clin Microbiol 37:3590–3593

    Google Scholar 

  29. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN et al (2001) Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997–1999. Clin Infect Dis 32(Suppl 2):S114–S132

    Google Scholar 

  30. Howe RA, Noel AR, Bowker KE, Walsh TR, MacGowan AP (2003) The prevalence of heterogenously vancomycin intermediate Staphylococcus aureus (hVISA) in the USA. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. C2-1828

  31. Cartolano GL, Cheron M, Benabid D, Leneveu M, Boisivon A (2004) Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin Microbiol Infect 10:448–451

    Google Scholar 

  32. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM et al (2003) Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997–2001. Clin Infect Dis 36:429–439

    Google Scholar 

  33. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA et al (2001) Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 39:2439–2444

    Article  Google Scholar 

  34. Tenover FC, Biddle JW, Lancaster MV (2001) Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 7:327–332

    Google Scholar 

  35. Wootton M, Avison AB, Bennett PM, Howe RA, Walsh TR (2003) Lack of expression of fmtB/mrp in vancomycin intermediate Staphylococcus aureus (VISA) and hetero (h) VISA phenotype: a new diagnostic marker. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. D-1892

  36. Sakoulas G, Eliopoulos GM, Moellering RC Jr, Novick RP, Venkataraman L, Wennersten C et al (2003) Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 187:929–938

    Article  Google Scholar 

  37. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr (2004) Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 38:1700–1705

    Google Scholar 

  38. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402

    Article  Google Scholar 

  39. Pavie J, Lefort A, Ploy MC, Massias L, Chau F, Garry L et al (2003) Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis. Antimicrob Agents Chemother 47:2018–2021

    Article  Google Scholar 

  40. Moore MR, Perdreau-Remington F, Chambers HF (2003) Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 47:1262–1266

    Article  Google Scholar 

  41. Moise PA, Forrest A, Birmingham MC, Schentag JJ (2002) The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 50:1017–1026

    Article  Google Scholar 

  42. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B (2002) Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34:1481–1490

    Google Scholar 

  43. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH (2000) Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin–dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 46:775–784

    Article  Google Scholar 

  44. Ariza J, Pujol M, Cabo J, Pena C, Fernandez N, Linares J et al (1999) Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet. 353:1587–1588

    Article  Google Scholar 

  45. Schwaber MJ, Wright SB, Carmeli Y, Venkataraman L, DeGirolami PC, Gramatikova A et al (2003) Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis 9:657–664

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases Department, Austin Health, Melbourne, Australia

    B. P. Howden, P. D. R. Johnson, P. G. P. Charles & M. L. Grayson

  2. Microbiology Department, Austin Health, Melbourne, Australia

    P. B. Ward

  3. Present address: Microbiology Department, Monash University, Wellington Road, Clayton, 3800, Melbourne, Victoria, Australia

    B. P. Howden

Authors
  1. B. P. Howden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. B. Ward
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. D. R. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. G. P. Charles
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. L. Grayson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. P. Howden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Howden, B.P., Ward, P.B., Johnson, P.D.R. et al. Low-level vancomycin resistance in Staphylococcus aureus—an Australian perspective. Eur J Clin Microbiol Infect Dis 24, 100–108 (2005). https://doi.org/10.1007/s10096-004-1261-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-004-1261-y

Keywords

Search

Navigation